390 related articles for article (PubMed ID: 25673052)
1. Biomarkers in preclinical cancer imaging.
Bernsen MR; Kooiman K; Segbers M; van Leeuwen FW; de Jong M
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(4):579-96. PubMed ID: 25673052
[TBL] [Abstract][Full Text] [Related]
2. Translational molecular imaging for cancer.
Pomper MG
Cancer Imaging; 2005 Nov; 5 Spec No A(Spec No A):S16-26. PubMed ID: 16361132
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers and imaging: physics and chemistry for noninvasive analyses.
Moyer BR; Barrett JA
Bioanalysis; 2009 May; 1(2):321-56. PubMed ID: 21083171
[TBL] [Abstract][Full Text] [Related]
4. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
[TBL] [Abstract][Full Text] [Related]
5. Imaging Mouse Models of Cancer.
Lyons SK
Cancer J; 2015; 21(3):152-64. PubMed ID: 26049694
[TBL] [Abstract][Full Text] [Related]
6. Correlating and Combining Genomic and Proteomic Assessment with In Vivo Molecular Functional Imaging: Will This Be the Future Roadmap for Personalized Cancer Management?
Basu B; Basu S
Cancer Biother Radiopharm; 2016 Apr; 31(3):75-84. PubMed ID: 27093341
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors.
Okarvi SM; Al Jammaz I
Nucl Med Biol; 2010 Apr; 37(3):277-88. PubMed ID: 20346867
[TBL] [Abstract][Full Text] [Related]
8. Targeting cytokine/chemokine receptors: a challenge for molecular nuclear medicine.
Signore A; Chianelli M; Bei R; Oyen W; Modesti A
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):149-56. PubMed ID: 12520385
[TBL] [Abstract][Full Text] [Related]
9. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
Amacher DE
Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
[TBL] [Abstract][Full Text] [Related]
10. The progress and promise of molecular imaging probes in oncologic drug development.
Kelloff GJ; Krohn KA; Larson SM; Weissleder R; Mankoff DA; Hoffman JM; Link JM; Guyton KZ; Eckelman WC; Scher HI; O'Shaughnessy J; Cheson BD; Sigman CC; Tatum JL; Mills GQ; Sullivan DC; Woodcock J
Clin Cancer Res; 2005 Nov; 11(22):7967-85. PubMed ID: 16299226
[TBL] [Abstract][Full Text] [Related]
11. Functional MRI and CT biomarkers in oncology.
Winfield JM; Payne GS; deSouza NM
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(4):562-78. PubMed ID: 25578953
[TBL] [Abstract][Full Text] [Related]
12. Radiopharmaceuticals as probes to characterize tumour tissue.
Alam IS; Arshad MA; Nguyen QD; Aboagye EO
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(4):537-61. PubMed ID: 25647074
[TBL] [Abstract][Full Text] [Related]
13. Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy.
Nilsson FY; Tolmachev V
Curr Opin Drug Discov Devel; 2007 Mar; 10(2):167-75. PubMed ID: 17436552
[TBL] [Abstract][Full Text] [Related]
14. Novel Approaches to Imaging Tumor Metabolism.
Tee SS; Keshari KR
Cancer J; 2015; 21(3):165-73. PubMed ID: 26049695
[TBL] [Abstract][Full Text] [Related]
15. Imaging surrogates of tumor response to therapy: anatomic and functional biomarkers.
Zhao B; Schwartz LH; Larson SM
J Nucl Med; 2009 Feb; 50(2):239-49. PubMed ID: 19164218
[TBL] [Abstract][Full Text] [Related]
16. Circulating Biomarkers for Prediction of Treatment Response.
Cappelletti V; Appierto V; Tiberio P; Fina E; Callari M; Daidone MG
J Natl Cancer Inst Monogr; 2015 May; 2015(51):60-3. PubMed ID: 26063889
[TBL] [Abstract][Full Text] [Related]
17. Imaging readouts as biomarkers or surrogate parameters for the assessment of therapeutic interventions.
Rudin M
Eur Radiol; 2007 Oct; 17(10):2441-57. PubMed ID: 17340100
[TBL] [Abstract][Full Text] [Related]
18. Functional Imaging Biomarkers: Potential to Guide an Individualised Approach to Radiotherapy.
Prestwich RJ; Vaidyanathan S; Scarsbrook AF
Clin Oncol (R Coll Radiol); 2015 Oct; 27(10):588-600. PubMed ID: 26133461
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies.
van der Meel R; Gallagher WM; Oliveira S; O'Connor AE; Schiffelers RM; Byrne AT
Drug Discov Today; 2010 Feb; 15(3-4):102-14. PubMed ID: 20035896
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients.
Beer AJ; Haubner R; Goebel M; Luderschmidt S; Spilker ME; Wester HJ; Weber WA; Schwaiger M
J Nucl Med; 2005 Aug; 46(8):1333-41. PubMed ID: 16085591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
